Platforms
Taking lentivirus as an example, this versatile tool finds widespread application in the realm of CGT. However, traditional lentivirus production relies on transient transfection production methods, resulting in low efficiency, intricate process steps, and exorbitant costs. EurekaBio is committed to resolving this issue. Leveraging its technological expertise and automated platform, EurekaBio has independently developed the EuLV™ system. This innovative system facilitates large-scale lentiviral vectors production utilizing stable producer cell lines. It has revolutionized lentivirus production, surmounting the technical bottleneck associated with scaling up. This breakthrough has considerably increased production efficiency, product consistency, and cost-effectiveness for lentiviral vectors.
The commercialization of CGT presents numerous unresolved challenges. EurekaBio remains steadfast in its commitment to iterate on its technology, addressing various aspects including technical hurdles, cost-effectiveness, regulatory compliance, and more. By doing so, the company aims to contribute to the ongoing development of CGT, offering new possibilities and opportunities for advancement.
Solutions
However, the complete closure and standardization of cell and gene therapy (CGT) product manufacturing presents a substantial challenge. Meeting regulatory requirements for production quality management often entails substantial investments in operations, labor, and quality control. EurekaBio is dedicated to developing fully closed and automated equipment that enhances cell preparation efficiency, mitigates contamination risks, streamlines process validation and improvement, establishes a unified quality control system, and ensures a secure, efficient, and quality-controlled production process for CGT products.
Moreover, the existing cell therapies available in the market are often prohibitively expensive for many individuals, necessitating the need for price reduction. Automation technology presents a viable solution to enhance production efficiency and effectively lower the cost of cell preparation. EurekaBio is steadfast in its commitment to introducing superior products to the industry, reducing overall costs, decreasing the price of cell therapies, expanding access to a broader patient population, fostering the advancement of the entire industry, and continuously pushing the boundaries of treatment.
Platforms
EurekaBio is dedicated to constant exploration, seamlessly blending multiple disciplines, and incorporating technologies like automation and artificial intelligence into life sciences. We foster close collaboration between bioengineering and life science-experienced engineering teams, employing an engineer’s mindset. Our aim is to develop highly efficient tools, streamline operations, reduce labor costs, overcome the constraints of manual processes, and enhance the overall efficiency of biological research. Through these efforts, we develop the core technologies and processes in the Cell and Gene Therapy (CGT) field, paving the way for groundbreaking possibilities in the realm of technology exploration.
+86-0755-86562586
.jpg)